Literature DB >> 29608744

SECOND CANCER RISK FROM RADIATION THERAPY FOR COMMON SOLID TUMORS DIAGNOSED IN REPRODUCTIVE-AGED FEMALES.

Michalis Mazonakis1, Stefanos Kachris2, John Damilakis1.   

Abstract

This study provided second cancer risk estimates from radiation therapy for common solid tumors presented in reproductive-aged females. Three-dimensional treatment plans were generated for 10 patients with cervical, uterine, rectal, lung or breast carcinomas. The organ equivalent dose (OED) and the lifetime attributable risk (LAR) for carcinogenesis to organs receiving high doses were estimated for all study participants with a mechanistic model. This model accounts for cell-killing, tissue repair and dose fractionation effects. The patient- and organ-specific relative risk was assessed by using the LARs and the respective lifetime intrinsic cancer risks for unexposed population. The OED of the organs-at-risk varied from 17.3 to 1423.1 rad. The LAR range for bladder, colon, lung and breast cancer induction was 0.12-0.14%, 10.88-12.71%, 1.66-8.62% and 0.71-3.75%, respectively. The relative risk for the appearance of bladder, colon, lung and breast malignancies following radiotherapy was up to 1.12, 4.05, 2.42 and 1.31, respectively.

Entities:  

Mesh:

Year:  2018        PMID: 29608744     DOI: 10.1093/rpd/ncy050

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  2 in total

1.  Risk for second bladder and rectal malignancies from cervical cancer irradiation.

Authors:  Michalis Mazonakis; Efrosyni Lyraraki; Maria Tolia; John Damilakis
Journal:  J Appl Clin Med Phys       Date:  2021-05-21       Impact factor: 2.102

2.  Increased burden of familial-associated early-onset cancer risk among minority Americans compared to non-Latino Whites.

Authors:  Qianxi Feng; Eric Nickels; Ivo S Muskens; Adam J de Smith; W James Gauderman; Amy C Yee; Charite Ricker; Thomas Mack; Andrew D Leavitt; Lucy A Godley; Joseph L Wiemels
Journal:  Elife       Date:  2021-06-22       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.